|Bid||0.4642 x 800|
|Ask||0.4621 x 2900|
|Day's range||0.4400 - 0.4695|
|52-week range||0.4400 - 3.1100|
|Beta (5Y monthly)||3.69|
|PE ratio (TTM)||N/A|
|Earnings date||03 Aug 2023 - 07 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.58|
Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. Both companies raced to bring a coronavirus vaccine to market.
Joining me today are Ocugen's chairman, CEO and co-founder; Dr. Shankar Musunuri, who will provide a business update; and our chief financial officer and chief business officer, Quan Vu, who will provide a financial update. Earlier this morning, we issued a press release detailing business and operational highlights for the first quarter of 2023.
With the business potentially at an important milestone, we thought we'd take a closer look at Ocugen, Inc.'s...
Investors were pleased, if not overwhelmingly so, with Ocugen's (NASDAQ: OCGN) latest set of quarterly results on Tuesday. The biotech published its fourth-quarter and full-year figures that morning, in addition to providing a business update. Ocugen is a clinical-stage biotech that has no revenue at the moment.
Joining me today are Ocugen's chairman, CEO, and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more detail on our financial results. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties.
Biotech companies are ripe with innovation. The two stocks I'll talk about here -- Novavax (NASDAQ: NVAX) and Ocugen (NASDAQ: OCGN) -- both have soared in recent years on optimism about potentially game-changing products. Novavax soared more than 2,700% in 2020 as investors bet on its investigational coronavirus vaccine.
Ocugen (NASDAQ: OCGN) soared into the spotlight -- and its stock soared too -- when it entered the COVID-19 vaccine race two years ago. Or has Ocugen left center stage for good? Let's consider one reason to buy Ocugen in 2023 -- and two reasons to sell.
Teladoc Health (NYSE: TDOC) sank 74% last year -- and for one particular reason. The telemedicine giant reported two billion-dollar noncash goodwill impairment charges. Both were linked to the acquisition of chronic-care specialist Livongo.
It's why the Nasdaq Composite lost a third of its value last year. Despite this turmoil, some growth stocks are expected to deliver phenomenal sales growth in 2023 -- even as their share prices come under pressure. What follows are three of the fastest-growing stocks on the planet in 2023.
When the curtain closed on 2022, the ageless Dow Jones Industrial Average, widely followed S&P 500, and growth-dependent Nasdaq Composite, respectively finished lower by 9%, 19%, and 33%. It was, collectively, the worst performance for Wall Street in 14 years. This is why most analyst price targets point to upside in equities.
Shares of clinical-stage biotech Ocugen (NASDAQ: OCGN) climbed as high as 14.2% on Thursday, to $1.29, shortly before noon. Ocugen focuses on gene and cell therapies and vaccines to treat retinal diseases, infectious diseases, and orthopedic conditions.
Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.
Like meme stocks will do from time to time, Ocugen (NASDAQ: OCGN) on Wednesday saw a notable price drop a day after a surge. The company was hit by quite a severe price target cut from an analyst, a move that ruined the party after Tuesday's post-earnings run-up. Before market open Wednesday, Noble Capital's Robert LeBoyer made a nearly 40% chop to his Ocugen target.
A third-quarter report, complete with clinical updates, is more than enough to satisfy the biotech's bulls.
Joining me today are Ocugen's chairman, CEO, and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more update on our financial results. Earlier this morning, we issued a press release detailing business activity for Q3 2022.
If you want to know who really controls Ocugen, Inc. ( NASDAQ:OCGN ), then you'll have to look at the makeup of its...
Since the three major U.S. indexes achieved their all-time highs between the midpoint of November 2021 and the first week of January, each has fallen into a bear market, with peak declines ranging from 22% to 38%. Of course, optimism can vary quite significantly on Wall Street. What follows are three high-octane growth stocks that select analysts and pundits believe offer upside ranging from 357% to as much as 571%!
Vaccine maker Ocugen (NASDAQ: OCGN) has had a tumultuous past 18 months on the stock market. The company's shares soared as it sought to make good on its intentions to enter the COVID-19 vaccine space, but with the delays it has encountered in this area, investors have largely given up.
Although it hasn't been the most popular coronavirus stock, Ocugen (NASDAQ: OCGN) clearly found some new fans on Thursday. In a one-two punch, Ocugen has appointed a new chief medical officer and chief scientific officer. The former is Robert Hopkins, a physician with over 20 years in both the public and private sectors of the healthcare industry.
Shares of clinical-stage biotech Ocugen (NASDAQ: OCGN) are on fire today. Mizuho's analyst noted that Ocugen's shares are only currently being valued at the commercial potential of its COVID-19 vaccine known as Covaxin. Ocugen is co-commercializing the vaccine in North America with its developer Bharat Biotech of India.
On that note, Ocugen (NASDAQ: OCGN) stock is down by more than 65% this year as the small biotech has struggled to commercialize a coronavirus vaccine. To remedy that issue, it's licensing a coronavirus vaccine called Covaxin from Bharat Biotech, an Indian pharmaceutical business. While it's already approved in India, the chances of Ocugen successfully commercializing Covaxin in the U.S. remain a question mark.
Commission-free trading platform Robinhood Markets grew in prominence helping newer investors participate in what remains one of the best ways to accumulate wealth over time. One example is Ocugen (NASDAQ: OCGN). Can Ocugen succeed in the COVID-19 vaccine market?
Joining me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more on our financial results. Earlier this morning, we issued a press release detailing business activity for Q2 2022.
Ocugen shares have struggled over the last year, declining more than 60% in value and vastly underperforming the S&P 500.
We feel now is a pretty good time to analyse Ocugen, Inc.'s ( NASDAQ:OCGN ) business as it appears the company may be...